Paul R. Edick

Paul R. Edick is a declared insider at 7 companies (chief executive); the most frequent names are Xeris Pharmaceuticals Inc, Xeris Biopharma Holdings, Inc. and Durata Therapeutics, Inc. Between 24 July 2012 and 31 January 2024, the trades on record add up to 46 filings.

On the market, this insider has only ever bought: 14 purchases, €1.3M in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 20 share grants and 1 option exercise.

Half of the purchases are above €38k and half below. Of 11 purchases, 5 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 31 January 2024 with a share grant in Xeris Biopharma Holdings, Inc. The most recent open-market purchase was published on 9 August 2023, 1,172 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.